Shares of Audentes Therapeutics Inc (NASDAQ:BOLD) have been assigned a consensus rating of “Hold” from the fifteen ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $34.55.

A number of research firms have commented on BOLD. Zacks Investment Research downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 9th. William Blair downgraded shares of Audentes Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 6th. BidaskClub downgraded shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 5th. Citigroup began coverage on shares of Audentes Therapeutics in a report on Monday, August 20th. They issued a “neutral” rating and a $40.00 price objective for the company. Finally, Raymond James reiterated a “hold” rating on shares of Audentes Therapeutics in a report on Friday, October 5th.

BOLD stock traded down $0.56 during mid-day trading on Friday, reaching $23.45. The company’s stock had a trading volume of 7,858 shares, compared to its average volume of 498,657. The company has a market cap of $998.52 million, a price-to-earnings ratio of -6.78 and a beta of 1.89. Audentes Therapeutics has a fifty-two week low of $19.62 and a fifty-two week high of $46.18.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.97) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.88) by ($0.09). During the same quarter in the prior year, the business posted ($0.88) EPS. As a group, analysts anticipate that Audentes Therapeutics will post -3.42 earnings per share for the current year.

In related news, Director Louis G. Lange sold 33,000 shares of the stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $37.38, for a total transaction of $1,233,540.00. Following the completion of the transaction, the director now owns 365,999 shares of the company’s stock, valued at approximately $13,681,042.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Suyash Prasad sold 10,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $36.88, for a total transaction of $368,800.00. Following the transaction, the vice president now directly owns 100 shares of the company’s stock, valued at approximately $3,688. The disclosure for this sale can be found here. Insiders have sold a total of 101,039 shares of company stock valued at $3,465,020 in the last 90 days. Insiders own 6.60% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Partner Investment Management L.P. purchased a new position in shares of Audentes Therapeutics during the 2nd quarter worth approximately $162,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Audentes Therapeutics during the 2nd quarter worth approximately $226,000. Quantitative Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the 2nd quarter worth approximately $231,000. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Audentes Therapeutics during the 2nd quarter worth approximately $232,000. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Audentes Therapeutics during the 2nd quarter worth approximately $332,000. 84.48% of the stock is owned by hedge funds and other institutional investors.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Featured Story: Reverse Stock Split

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.